Actinogen Medical Ltd has released a press release.
ACW Appendix 4E and 2022 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW CEO presentation to Spark Plus Aust Equities Day
- Application for quotation of securities - ACW
- ACW announces Phase 2 trial designs for AD & MDD
- Actinogen trial results & strategic update presentation
- Actinogen prioritizes Alzheimers Disease & Depression
Later from Actinogen Medical
- Actinogen FY22 Results - Accelerating Clinical Development
- ACW announces positive Alzheimers Disease clinical results
- ACW clinical biomarker study webcast presentation
- R&D tax incentive rebate received
- First patient treated in XanaCIDD Phase 2 Depression Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical